9030 Federal Register / Vol. 76, No. 32 / Wednesday, February 16, 2011 / Notices 

Application Number of 

respondents 

Responses 

per 

respondent 

Total 

responses 

Hours per 

response 

Total burden 

hours 

Waiver Request ................................................................... 10 1 10 6.5 65 

Total .............................................................................. 10 1 10 6.5 65 

E-mail comments to 

paperwork@hrsa.gov or mail the HRSA 

Reports Clearance Officer, Room 10–33, 

Parklawn Building, 5600 Fishers Lane, 

Rockville, MD 20857. Written comments 

should be received within 30 days of 

this notice. 

Dated: February 10, 2011. 

Reva Harris, 

Acting Director, Division of Policy and 

Information Coordination. 

[FR Doc. 2011–3528 Filed 2–15–11; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Commission on Childhood 

Vaccines; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Public Law 92–463), notice is hereby 

given of the following meeting: 

Name: Advisory Commission on 

Childhood Vaccines (ACCV). 

Date And Time: March 3, 2011, 9 a.m. 

to 5 p.m. EDT, March 4, 2011, 9 a.m. to 

12 p.m. EDT. 

Place: Parklawn Building (and via 

audio conference call), Conference 

Rooms G & H, 5600 Fishers Lane, 

Rockville, MD 20857. 

The ACCV will meet on Thursday, 

March 3 from 9 a.m. to 5 p.m. (EDT) and 

on Friday, March 4 from 9 a.m. to 12 

p.m. (EDT). The public can join the 

meeting via audio conference call by 

dialing 1–800–369–3104 on March 3 

and March 4 and providing the 

following information: 

Leader’s Name: Dr. Geoffrey Evans. 

Password: ACCV. 

Agenda: The agenda items for the 

March meeting will include, but are not 

limited to: updates from the Division of 

Vaccine Injury Compensation (DVIC), 

Department of Justice (DOJ), National 

Vaccine Program Office, Immunization 

Safety Office (Centers for Disease 

Control and Prevention), National 

Institute of Allergy and Infectious 

Diseases (National Institutes of Health), 

Center for Biologics, Evaluation and 

Research (Food and Drug 

Administration), a discussion on the 

VICP outreach efforts, and a review of 

Vaccine Information Statements (VISs). 

A draft agenda and additional meeting 

materials will be posted on the ACCV 

Web site (http://www.hrsa.gov/ 

vaccinecompensation/accv.htm) prior to 

the meeting. Agenda items are subject to 

change as priorities dictate. 

Public Comment: Persons interested 

in providing an oral presentation should 

submit a written request, along with a 

copy of their presentation to: Annie 

Herzog, DVIC, Healthcare Systems 

Bureau (HSB), Health Resources and 

Services Administration (HRSA), Room 

11C–26, 5600 Fishers Lane, Rockville, 

Maryland 20857 or e-mail: 

aherzog@hrsa.gov. Requests should 

contain the name, address, telephone 

number, e-mail address, and any 

business or professional affiliation of 

the person desiring to make an oral 

presentation. Groups having similar 

interests are requested to combine their 

comments and present them through a 

single representative. The allocation of 

time may be adjusted to accommodate 

the level of expressed interest. DVIC 

will notify each presenter by e-mail, 

mail or telephone of their assigned 

presentation time. Persons who do not 

file an advance request for a 

presentation, but desire to make an oral 

statement, may announce it at the time 

of the comment period. Public 

participation and ability to comment 

will be limited to space and time as it 

permits. 

FOR FURTHER INFORMATION CONTACT: 

Anyone requiring information regarding 

the ACCV should contact Annie Herzog, 

DVIC, HSB, HRSA, Room 11C–26, 5600 

Fishers Lane, Rockville, MD 20857; 

telephone (301) 443–6593 or e-mail: 

aherzog@hrsa.gov. 

Dated: February 10, 2011. 

Reva Harris, 

Acting Director, Division of Policy and 

Information Coordination. 

[FR Doc. 2011–3527 Filed 2–15–11; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Ancillary Studies in 

Immunomodulation Clinical Trials (R01). 

Date: March 10, 2011. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: James T. Snyder, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities/ 

NIAID, National Institutes of Health, 6700B 

Rockledge Drive, MSC 7616, Room #3257, 

Bethesda, MD 20892–7616, 301–435–1614, 

james.snyder@nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Genetics of Lupus. 

Date: March 11, 2011. 

Time: 11:30 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, 3136, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: Wendy F. Davidson, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

DHHS/NIH/NIAID, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892, 301–402– 

8399, davidsonw@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 76, No. 32 / Wednesday, February 16, 2011 / Notices 9031 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 10, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–3483 Filed 2–15–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Inherited 

Disease Research Access Committee. 

Date: March 11, 2011. 

Time: 11:30 a.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Camilla E. Day, PhD, 

Scientific Review Officer, CIDR, National 

Human Genome Research Institute, National 

Institutes of Health, 5635 Fishers Lane, Suite 

4075, Bethesda, MD 20892, 301–402–8837, 

camilla.day@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: February 10, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–3482 Filed 2–15–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, NIAMS. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, NIAMS. 

Date: March 3–4, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate the 

Molecular Immunology and Inflammation 

Branch and the Laboratory of Skin Biology. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 4C32, Bethesda, MD 20892. 

Contact Person: John J. O’Shea, MD, PhD, 

Scientific Director, National Institute of 

Arthritis & Musculoskeletal and Skin 

Diseases, Building 10, Room 9N228, MSC 

1820, Bethesda, MD 20892, (301) 496–2612, 

osheaj@arb.niams.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: February 9, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–3481 Filed 2–15–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Library of 

Medicine Special Emphasis Panel R25. 

Date: March 16, 2011. 

Time: 12 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Library of Medicine, 6705 

Rockledge Drive, Suite 301, Bethesda, MD 

20817 (Telephone Conference Call). 

Contact Person: Zoe H. Huang, MD, 

Scientific Review Officer, Extramural 

Programs, National Library of Medicine, NIH, 

6705 Rockledge Drive, Suite 301, Bethesda, 

MD 20892–7968, 301–594–4937, 

huangz@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.879, Medical Library 

Assistance, National Institutes of Health, 

HHS) 

Dated: February 10, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–3480 Filed 2–15–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel; CDRC 

Member Conflicts Review. 

Date: March 9, 2011. 

Time: 10:30 a.m. to 1 p.m. 

mstockstill on DSKH9S0YB1PROD with NOTICES